Watch These Grail Price Levels After Med Tech Company's Stock Soared 64% Last Week

Grail Stock Performance and Technical Analysis - Grail (GRAL) shares surged to a new record high, gaining 64% last week amid optimism about the company's early-detection cancer screening blood tests [2][4] - The stock's rally was fueled by comments from Oracle's Larry Ellison, who highlighted the potential of combining early detection blood tests with AI and gene sequencing to develop personalized cancer vaccines [3] - Grail shares broke out above the neckline of a cup and handle pattern on Thursday, with gains continuing through Friday's session, supported by the highest trading volume since mid-December [5] Technical Indicators and Price Targets - The relative strength index (RSI) confirms bullish price momentum, though it registered an overbought reading on Friday, suggesting potential for near-term profit-taking [6] - Using the measured move technique, an upside target of $46 is projected by applying a 100$23 [7][8] - Key support levels to monitor during pullbacks include $23, near the cup and handle pattern's neckline, and$20, a psychological level near a trendline connecting historical peaks and troughs [9][10] Industry Context and Market Focus - Grail's early-detection cancer screening blood tests are gaining attention in the medical technology sector, with potential applications in AI and gene sequencing for personalized cancer vaccines [2][3] - The company, spun off from Illumina Health last June, remains in focus as its stock continues to attract investor interest following its recent breakout and strong performance [4][11]